Treatment of Posterior Uveitis With a Fluocinolone Acetonide Implant

Correspondence: David G. Callanan, MD, Texas Retina Associates, 1001 N Waldrop Dr, Ste 512, Arlington, TX 76012 ([email protected]).

Submitted for Publication: January 20, 2008; final revision received May 17, 2008; accepted May 19, 2008.

Author Contributions: All of the authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Financial Disclosure: Drs Callanan, Jaffe, Martin, and Pearson were consultants for Bausch & Lomb during either the writing or conduct of this study, and Dr Pearson also received travel support. Dr Pearson has been a consultant for pSivida (formerly Control Delivery Systems), owns stock in the company, and has received research support. He also holds patents at the University of Kentucky that may cover the implant technology, and he could be entitled to royalties. Dr Comstock is an employee of Bausch & Lomb.

Funding/Support: This work was sponsored by Bausch & Lomb, Rochester, New York.

Previous Presentations: These data were presented in part as posters at the 2005 Annual Meeting of the Association for Research in Vision and Ophthalmology; May 1–5, 2005; Fort Lauderdale, Florida; and at the 2006 Annual Meeting of the Association for Research in Vision and Ophthalmology; April 30 to May 4, 2006; Fort Lauderdale, Florida.

Additional Contributions: We thank and acknowledge the investigators: Rajiv Anand, MD, Dallas, Texas; Brian Berger, MD, Austin, Texas; David Callanan, MD, Arlington, Texas; Kakarla V. Chalam, MD, Jacksonville, Florida; Janet L. Davis, MD, University of Miami, Miami, Florida; Pravin U. Dugel, MD, Phoenix, Arizona; J. P. Dunn Jr, MD, Wilmer Eye Institute, Baltimore, Maryland; C. Stephen Foster, MD, Massachusetts Eye and Ear Infirmary, Boston; William Freeman, MD, University of California, San Diego, La Jolla; Debra A. Goldstein, MD, University of Illinois at Chicago; Allen Ho, MD, Wills Eye Hospital, Philadelphia, Pennsylvania; Glenn J. Jaffe, MD, Duke University, Durham, North Carolina; Baruch Kuppermann, MD, PhD, University of California, Irvine; Paul Latkany, MD, New York, New York; Careen Y. Lowder, MD, PhD, Cole Eye Institute, Cleveland, Ohio; Daniel F. Martin, MD, Emory Eye Center, Atlanta, Georgia; Pauline Merrill, MD, Rush University, Chicago; Ramana Moorthy, MD, Indianapolis, Indiana; Lawrence Morse, MD, PhD, University of California, Davis; Stuart Noorily, MD, Teaneck, New Jersey; Peter Pavan, MD, University of South Florida, Tampa; Chee Soon Phaik, MD, Singapore; Michael B. Raizman, MD, Tufts–New England Medical Center, Boston; James T. Rosenbaum, MD, Casey Eye Institute, Portland, Oregon; John Sheppard, Jr, MD, Eastern Virginia Medical School, Norfolk; Russell Van Gelder, MD, PhD, Barnes Retina Institute, St Louis, Missouri; and Albert Vitale, MD, John A. Moran Eye Center, University of Utah, Salt Lake City. We also thank and acknowledge the members of the Data and Safety Monitoring Committee: Alexander Brucker, MD, Scheie Eye Institute, Philadelphia (chair); Karen Gehrs, MD, University of Iowa, Iowa City; Lee Jampol, MD, Northwestern University, Chicago; Mark Johnson, MD, University of Michigan, Ann Arbor; Theodore Colton, ScD, Boston University, Boston; David Musch, PhD, University of Michigan, Ann Arbor; and Robert Levine, MD, Yale University, New Haven, Connecticut; as well as the Retinal Diseases Image Analysis Center, University Hospitals Case Medical Center, Cleveland. Melvin F. Simoyi, PhD, and Heleen H. DeCory, PhD, provided assistance in preparing the manuscript.